GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2010

Baxter Doles Out $20M for Commercial Rights to Kamada’s Emphysema Therapy

  • Baxter International is paying $20 million upfront to Kamada for exclusive commercial rights to Glassia™, a liquid alpha1-proteinase inhibitor for the treatment of emphysema. The deal includes rights in Australia, Canada, New Zealand, and the U.S.

    In addition to the $20 million cash payment, the agreement also includes a provision under which Kamada has agreed, for a limited period of time, not to initiate or enter any discussions or agreements relating to the commercialization of Glassia in certain other geographic areas.

    Under a separate license agreement, Baxter has been granted the right to process Glassia and will seek necessary regulatory approvals to enable it to do so. Also under this agreement, Baxter may make additional payments of up to $25 million related to the achievement of certain commercial milestones and the execution of technology transfer related to the production of the therapy. Kamada will also earn royalties on product sales.

    Baxter expects to introduce Glassia in the U.S. during the fourth quarter. It will pursue distribution licenses for the drug in the other countries for which it has obtained rights.

    Glassia was approved by the FDA on July 1. It is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (alpha1-PI), also known as alpha1-antitrypsin deficiency.

    “The agreement with Kamada underscores Baxter’s commitment to expanding the diagnosis of alpha1-antitrypsin deficiency by bringing new and innovative therapeutic options to alpha-1 patients and their treating physicians,” comments Larry Guiheen, president of global biopharmaceuticals, Baxter BioScience.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »